jimandin õhukese polümeerikattega tablett
medochemie limited - sitagliptiin - õhukese polümeerikattega tablett - 25mg 98tk; 25mg 28tk; 25mg 84tk; 25mg 30tk; 25mg 56tk; 25mg 14tk; 25mg 90tk
maysiglu õhukese polümeerikattega tablett
krka, d.d., novo mesto - sitagliptiin - õhukese polümeerikattega tablett - 50mg 90tk; 50mg 98tk; 50mg 56tk; 50mg 28tk; 50mg 14tk; 50mg 30tk; 50mg 60tk
maysiglu õhukese polümeerikattega tablett
krka, d.d., novo mesto - sitagliptiin - õhukese polümeerikattega tablett - 25mg 60tk; 25mg 30tk; 25mg 56tk; 25mg 98tk; 25mg 90tk; 25mg 14tk; 25mg 28tk
maysiglu õhukese polümeerikattega tablett
krka, d.d., novo mesto - sitagliptiin - õhukese polümeerikattega tablett - 100mg 56tk; 100mg 60tk; 100mg 14tk; 100mg 30tk; 100mg 90tk
juzina õhukese polümeerikattega tablett
gedeon richter plc. - sitagliptiin - õhukese polümeerikattega tablett - 100mg 60tk; 100mg 90tk; 100mg 56tk; 100mg 84tk; 100mg 30tk; 100mg 28tk
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
agil® 100 ec
adama - emulsioonikontsentraat - propakvisafop - herbitsiidid
banjo forte®
adama - suspensioonikontsentraat - dimetomorf + fluasinaam - fungitsiidid
cleave®
adama - suspo-emulsioon - florasulaam + fluroksüpüür - herbitsiidid
kantik®
adama - emulsioonikontsentraat - fenpropidiin + prokloraas + tebukonasool - fungitsiidid